NCT04952597 2024-10-26
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
BeiGene
Phase 2 Completed
BeiGene
Celgene
Merck KGaA, Darmstadt, Germany
GlaxoSmithKline
Eli Lilly and Company